$5.52
2.99% yesterday
NYSE, May 20, 10:00 pm CET
ISIN
US03237H1014
Symbol
AMLX
Sector
Industry

Amylyx Pharmaceuticals Stock price

$5.52
+1.29 30.50% 1M
+0.29 5.54% 6M
+1.74 46.03% YTD
+3.68 200.00% 1Y
-3.18 36.55% 3Y
-12.55 69.45% 5Y
-12.55 69.45% 10Y
NYSE, Closing price Tue, May 20 2025
+0.16 2.99%
ISIN
US03237H1014
Symbol
AMLX
Sector
Industry

Key metrics

Market capitalization $492.06m
Enterprise Value $289.37m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales -227.85
P/B ratio (TTM) P/B ratio 2.44
Revenue growth (TTM) Revenue growth -100.32%
Revenue (TTM) Revenue $-1.27m
EBIT (operating result TTM) EBIT $-171.35m
Free Cash Flow (TTM) Free Cash Flow $-207.08m
Cash position $204.07m
EPS (TTM) EPS $-3.10
P/E forward negative
Short interest 5.19%
Show more

Is Amylyx Pharmaceuticals a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Amylyx Pharmaceuticals Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Amylyx Pharmaceuticals forecast:

5x Buy
83%
1x Hold
17%

Analyst Opinions

6 Analysts have issued a Amylyx Pharmaceuticals forecast:

Buy
83%
Hold
17%

Financial data from Amylyx Pharmaceuticals

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
-1.27 -1.27
100% 100%
100%
- Direct Costs 8.97 8.97
93% 93%
-
-10 -10
104% 104%
-
- Selling and Administrative Expenses 72 72
64% 64%
-
- Research and Development Expense 89 89
36% 36%
-
-171 -171
113% 113%
-
- Depreciation and Amortization 0.75 0.75
38% 38%
-
EBIT (Operating Income) EBIT -171 -171
111% 111%
-
Net Profit -219 -219
208% 208%
-

In millions USD.

Don't miss a Thing! We will send you all news about Amylyx Pharmaceuticals directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Amylyx Pharmaceuticals Stock News

Neutral
Business Wire
9 days ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Announces Positive Long-Term Results from Phase 2 HELIOS Clinical Trial of AMX0035 in People with Wolfram Syndrome.
Neutral
Seeking Alpha
11 days ago
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX ) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Lindsey Allen - Vice President Investor Relations and Communications Justin Klee - Co-CEO Camille Bedrosian - Chief Medical Officer Jim Frates - Chief Financial Officer Josh Cohen - Co-CEO Conference Call Participants Michael DiFiore - Evercore ISI Marc Goodman - Leerink Tim ...
Neutral
Business Wire
13 days ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals reports First Quarter 2025 financial results.
More Amylyx Pharmaceuticals News

Company Profile

Amylyx Pharmaceuticals, Inc. operates as a biopharmaceutical company, which engages in the provision of disease-modifying solutions for neurodegenerative diseases. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.

Head office United States
CEO Josh Klee
Employees 123
Founded 2013
Website www.amylyx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today